

[Chloroquine](#)

Not recommended as an essential medicine

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.3. Antimalarial medicines](#) [6.5.3.1. Antimalarial medicines](#) > [Medicines for curative treatment](#)

ATC codes: [P01BA01](#)

Indication

Malaria due to Plasmodium falciparum ICD11 code: [1F40](#)

INN

Chloroquine

Medicine type

Chemical agent

List type

Core

Formulations

Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)

Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)

Oral > Solid: 150 mg tablet (as phosphate or sulfate) ; 100 mg tablet (as phosphate or sulfate)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1982 ([TRS 685](#))

Changed in 1995 ([TRS 867](#))

Changed in 2003 ([TRS 920](#))

Removed in 2007 ([TRS 946](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Chloroquine](#)

DrugBank

[Chloroquine](#)

Summary of evidence and Expert Committee recommendations

Chloroquine was maintained on the core list, but for use only in the treatment of P. vivax, P. ovale and P. malariae infections.